Cobb Leah H, Bailey Victoria O, Liu Yuan F, Teixido Michael T, Rizk Habib G
Department of Otolaryngology; Medical University of South Carolina, Charleston, SC, USA.
Department of Otolaryngology, Head and Neck Surgery, Loma Linda University Health, Loma Linda, CA, USA.
Auris Nasus Larynx. 2023 Feb;50(1):70-80. doi: 10.1016/j.anl.2022.05.011. Epub 2022 Jun 2.
To examine the relationship of 25hydroxyvitamin D serum levels with BPPV incidence and recurrence rates.
A retrospective cross-sectional, case-controlled study with follow-up phone survey was performed on patients diagnosed with BPPV between 05/2017-05/2020, who had available 25hydroxyvitamin D serology. Patients were seen at a multidisciplinary, vestibular-focused, neurotology clinic at a tertiary referral center. Controls consisted of subjects from the National Health and Nutrition Examination Survey (NHANES), and a locoregional age, sex, and race-matched group of patients from our institution.
Our BPPV cohort consisted of 173 patients (mean age 66.2 ± 11.8 years), who were predominately female (75.7%) and Caucasian (76.3%). Almost all age subgroups (BPPV, NHANES, and locoregional groups) ≤60 years old had insufficient levels of vitamin D. However, the overall BPPV cohort had a significantly higher vitamin D level than the NHANES control (31.4 ± 16.5 v. 26.0 ± 11.2 ng/mL, d=0.474 [0.323, 0.626]). There was no significant difference when compared to the overall locoregional control (31.4 ± 20.5 ng/mL). Migraines were significantly correlated to increased BPPV recurrence rates on univariate (beta=0.927, p=0.037, 95% CI: [0.057, 1.798]) and multiple regression analyses (beta=0.231, 95% CI: [0.024, 2.029], p=0.045). Furthermore, patients with BPPV recurrences had significantly lower levels of vitamin D at initial presentation when compared to patients with no recurrences (29.0 ± 12.0 v. 37.6 ± 18.3 ng/mL, d=0.571[0.139,1.001]).
Many BPPV patients in our cohort had insufficient vitamin D levels, and patients with BPPV recurrences had insufficient and significantly lower vitamin D levels than those without. As a readily available and affordable supplement, vitamin D may be used as an adjunct treatment but prospective studies should be done to confirm if it can prevent or reduce recurrence.
研究血清25-羟维生素D水平与良性阵发性位置性眩晕(BPPV)发病率及复发率之间的关系。
对2017年5月至2020年5月期间诊断为BPPV且有可用的25-羟维生素D血清学检查结果的患者进行了一项回顾性横断面病例对照研究,并进行随访电话调查。患者在一家三级转诊中心的多学科、专注于前庭的神经耳科诊所就诊。对照组包括来自美国国家健康与营养检查调查(NHANES)的受试者,以及来自我们机构的局部年龄、性别和种族匹配的患者组。
我们的BPPV队列由173名患者组成(平均年龄66.2±11.8岁),其中女性占主导(75.7%),白种人占76.3%。几乎所有≤60岁的年龄亚组(BPPV组、NHANES组和局部组)维生素D水平均不足。然而,BPPV队列的总体维生素D水平显著高于NHANES对照组(31.4±16.5 vs. 26.0±11.2 ng/mL,d=0.474[0.323, 0.626])。与总体局部对照组(31.4±20.5 ng/mL)相比,无显著差异。在单因素分析(β=0.927,p=0.037,95%CI:[0.057, 1.798])和多元回归分析(β=0.231,95%CI:[0.024, 2.029],p=0.045)中,偏头痛与BPPV复发率增加显著相关。此外,与无复发的患者相比,BPPV复发患者在初次就诊时的维生素D水平显著更低(29.0±12.0 vs. 37.6±18.3 ng/mL,d=0.571[0.139, 1.001])。
我们队列中的许多BPPV患者维生素D水平不足,且BPPV复发患者的维生素D水平不足且显著低于未复发患者。作为一种易于获得且价格低廉的补充剂,维生素D可作为辅助治疗,但应进行前瞻性研究以确认其是否能预防或降低复发。